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Abstract
Aberrant fucosylation in cancer cells is considered as a signature of malignant cell transformation
and it is associated with tumor progression, metastasis and resistance to chemotherapy. Specifically,
in colorectal cancer cells, increased levels of the fucosylated Lewisx antigen are attributed to the
deregulated expression of pertinent fucosyltransferases, like fucosyltransferase 4 (FUT4) and fucosyl-
transferase 9 (FUT9). However, the lack of experimental models closely mimicking cancer-specific
regulation of fucosyltransferase gene expression has, so far, limited our knowledge regarding the
substrate specificity of these enzymes and the impact of Lewisx synthesis on the glycome of colorec-
tal cancer cells. Therefore, we sought to transcriptionally activate the Fut4 and Fut9 genes in the well-
known murine colorectal cancer cell line, MC38, which lacks expression of the FUT4 and FUT9
enzymes. For this purpose, we utilized a physiologically relevant, guide RNA-based model of de novo
gene expression, namely the CRISPR-dCas9-VPR system. Induction of the Fut4 and Fut9 genes in
MC38 cells using CRISPR-dCas9-VPR resulted in specific neo-expression of functional Lewisx antigen
on the cell surface. Interestingly, Lewisx was mainly carried by N-linked glycans in both MC38-FUT4
and MC38-FUT9 cells, despite pronounced differences in the biosynthetic properties and the expres-
sion stability of the induced enzymes. Moreover, Lewisx expression was found to influence core-
fucosylation, sialylation, antennarity and the subtypes of N-glycans in the MC38-glycovariants. In
conclusion, exploiting the CRISPR-dCas9-VPR system to augment glycosyltransferase expression is
a promising method of transcriptional gene activation with broad application possibilities in glyco-
biology and oncology research.
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Introduction
Over the last few years, genome engineering through the clustered
regularly interspaced short palindromic repeats (CRISPR)-Cas9 sys-
tem has received increased attention and is gradually becoming a
method of choice for studying various biological processes, includ-
ing protein and lipid glycosylation. To date, the CRISPR-Cas9 tech-
nology is considered as the most precise, efficient and cost-effective
gene editing tool available (Chandrasegaran and Carroll 2016).
Despite the vast complexity of the mammalian glycome, glyco-
syltransferases have been genetically classified as members of hom-
ologous isoenzyme families that influence glycosylation globally
(Hansen et al. 2015). Therefore, different applications of the
CRISPR-Cas9 system can serve as the ultimate toolbox for investi-
gating the biological functions of glycans, through genetic abroga-
tion of the respective biosynthetic pathways in primary cells and cell
lines (Narimatsu et al. 2018). For example, the gene knock-out
application of CRISPR-Cas9 has already assisted to a better under-
standing of how glycosylation influences human leukocyte adhesion
to endothelial cells (Stolfa et al. 2016) or the transport of galectins
to the cell surface (Stewart et al. 2017).
Besides the classical gene editing (e.g gene knock-out) applications,
tools for successful regulation of gene expression using the CRISPR-
Cas9 technology have been also introduced, such as the CRISPR-
dCas9-VPR system (Chavez et al. 2015). In sharp contrast with trad-
itional methods of gene overexpression with the use of selected cDNA
clones, the CRISPR-dCas9-VPR toolkit facilitates de novo gene tran-
scription that occurs physiologically within the nucleus of the cell and
its native chromosomal context. In this case, one or multiple guide
RNA (gRNA) sequences specifically target the promoter region of the
gene of interest, resulting in direct recruitment of the catalytically
inactive Cas9 nuclease (called defective or deactivated Cas9) to this
site. However, a major difference compared to the CRISPR-Cas9 gene
editing tools is that the dCas9 protein is now fused to a hybrid tripar-
tite activation domain (VP64-p53-Rta), known as VPR. The subse-
quent interaction between the VPR activation unit of dCas9 and the
RNA polymerase II and/or other transcription factors eventually drives
the expression of the gene of interest (Figure 1A).
We hypothesized that induction of gene expression using the
CRISPR-dCas9-VPR system could be reliably applied to glycobiol-
ogy research through the efficient and specific transcriptional pro-
gramming of glycosyltransferase genes. Importantly, by employing
CRISPR-dCas9-VPR, all the critical regulatory mechanisms asso-
ciated with glycosyltransferase gene expression can be easily unrav-
eled, since they are still active in this model and not simply
bypassed. In the past, significant changes in glycosylation due to the
use of cDNA clones have been observed (van Leeuwen et al. 2006).
Moreover, complex epigenetic modifications of genes involved in
protein and lipid glycosylation (Zoldos et al. 2010, Lauc et al.
2014) that are often completely missed or undermined when cDNA
clones are used, can be now further assessed with CRISPR-dCas9-
VPR (Lo and Qi 2017). This is of utmost importance for dissecting
the mechanisms that lead to an aberrant expression profile of certain
glycosyltransferases under pathological conditions, as in the case of
cancer.
In general, tumor cells are characterized by a tremendous change
in their cell surface glycome, as a result of genetic or epigenetic
alterations in the expression of particular glycosyltransferase genes.
Specifically, cancer cells exhibit elevated levels of fucosylation, sialy-
lation and branched N-linked glycans compared to their healthy
counterparts, due to overexpression of certain genes involved in the
respective biosynthetic pathways (Pinho and Reis 2015). Therefore,
exploitation of the CRISPR-dCas9-VPR system for transcriptional
reprogramming of genes related to cancer glycosylation could pro-
vide a better insight into the role of individual glycosyltransferases,
as well as the impact of tumor-associated glycans on cancer cell
biology.
One well-known tumor-associated glycan motif is the fucosylated
Lewisx trisaccharide (Galβ1-4(Fucα1-3)GlcNAcβ1), alternatively
known as the stage-specific embryonic antigen 1 (SSEA-1) or CD15
antigen. It is a member of the human histo-blood group antigen sys-
tem, broadly known as the Lewis antigen system. Overexpression of
this epitope has been reported in many types of cancer, including
colorectal cancer (Blanas et al. 2018). Lewisx is recognized by desig-
nated C-type lectin receptors (CLRs) expressed on antigen-presenting
cells, such as DC-SIGN (CD209) in humans (Appelmelk et al. 2003)
and MGL-1 (CD301a) in mice (Singh et al. 2009). Although different
fucosyltransferases are responsible for its synthesis, fucosyltransferase
4 (FUT4) and fucosyltransferase 9 (FUT9) are the most competent
ones in synthesizing Lewisx (Mondal et al. 2018). Notably, both
enzymes are strongly associated with colorectal cancer progression,
metastasis and resistance to chemotherapy (Giordano et al. 2015,
Auslander et al. 2017). However, the biosynthetic properties of the
FUT4 and FUT9 enzymes and the potential effect of increased Lewisx
expression on the glycosylation status of colorectal cancer cells have
not been fully investigated yet.
To this end, we are the first to apply the CRISPR-dCas9-VPR
targeting system to transcriptionally activate the Fut4 and Fut9
fucosyltransferase genes in MC38 cells, a murine colorectal adeno-
carcinoma cell line that is commonly used in pre-clinical mouse
models for this disease (McIntyre et al. 2015, Zhao et al. 2017).
Following this approach, we successfully generated FUT4- or FUT9-
expressing MC38 glyco-engineered cell lines and examined changes
in their respective glycosylation profiles, focusing on biosynthesis of
the fucosylated Lewisx determinant and its impact on the cancer cell
glycome. We believe that this novel methodology of gene expression
can be further applied both to human and murine glycosyltrans-
ferases involved in tumorigenesis or other disorders and thus set the
framework to elucidate the exact implication of these enzymes (or
their synthesized glycan structures) in different aspects of disease
pathogenesis. Moreover, we consider our study as a representative
example of how advances in the CRISPR technology can benefit
research investigations focused on glycosylation, thus highlighting
its role in health and disease.
Results
Design, selection and quality control of the murine Fut4
and Fut9 gene targeting gRNA sequences
A key factor for precise, but also efficient, gene targeting using the
CRISPR-dCas9-VPR system is the design of the corresponding
gRNA sequences. To date, several prediction tools have been devel-
oped for this purpose (Hsu et al. 2013, Doench et al. 2014, Heigwer
et al. 2014, Montague et al. 2014), providing detailed lists of pro-
posed gRNAs to the user. However, the final decision about the
exact gRNAs that should be used remains a big challenge and a
protocol for precisely narrowing down all the possible options is still
missing. Therefore, we here present the workflow followed by us for
the selection and quality control of the designed gRNAs targeting
the murine Fut4 and Fut9 genes (Figure 1B). Importantly, we believe
that this process can be easily adapted and utilized for the selection
138 A Blanas et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/glycob/article-abstract/29/2/137/5198004 by R
adboud U
niversity user on 28 April 2020
of gRNA sequences that specifically target any other (glyco)gene of
interest.
In more detail, we initially reviewed the literature giving emphasis
to the promoter regions as well as the known regulatory elements
that have been implicated in determining the expression of the Fut4
and Fut9 fucosyltransferase genes. Then, we designed 20-nucleotide
gRNAs targeting sequences in close proximity to the transcriptional
start site of each gene, since transcriptional gene activation is most
effective when the target sequence is within the range −400 and
+100 bp of the corresponding transcriptional start site (Gilbert et al.
2014, Konermann et al. 2015, Liao et al. 2017). The gRNA
sequences were designed using the E-CRISP platform (http://www.e-
crisp.org/E-CRISP/) (Heigwer et al. 2014) and we carefully selected
only those gRNAs that could be validated by a second prediction
tool, such as the CRISPR design (http://crispr.mit.edu/) (Hsu et al.
2013). In order to exclude non-specific gRNAs with potential off-
target effects from our analysis, we exploited the Basic Local
Alignment Search Tool (BLAST) and further selected those ones that
had the minimum complementarity score (<15) with respect to the
whole-genome. Finally, by using the transcription factor binding-site
prediction tool Tfsitescan (http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl),
we ended up with two gRNAs for each FUT gene (Supplementary
Table I), targeting transcription factor binding-free sequences in close
proximity to the transcriptional start site and fulfilling the remainder
of the criteria mentioned above. These gRNA sequences were con-
sidered as “optimal” according to our established gRNA quality con-
trol system and were cloned into the appropriate expression vector for
the generation of the final gRNA constructs (Figure 1B).
Fig. 1. Model and experimental design for the CRISPR-dCas9-VPR system. (A) Principle of transcriptional gene activation using the CRISPR-dCas9-VPR technol-
ogy. One or multiple guide RNA (gRNA) sequences that specifically target the complementary promoter region of the (glyco)gene of interest, result in direct
recruitment of the catalytically inactive Cas9 nuclease (known as defective or deactivated Cas9) to this site. The following interaction between VPR (VP64-p65-
Rta chimeric activator fused to the C-terminus of dCas9) and RNA polymerase II drives the induction of target gene expression. (B) Overview of the five-step
experimental design applied for transcriptional activation of the murine Fut4 and Fut9 genes using the CRISPR-dCas9-VPR technology.
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Transcriptional activation of the Fut4 and Fut9 genes
leads to specific neo-expression of the Lewisx antigen
in MC38-glycovariants
Although high expression of fucosylated epitopes has been observed
in many human colorectal cancer cell lines (Holst et al. 2016), our
MC38 wild type cells did not express any fucosylated type I or type II
Lewis antigens on their cell surface (Supplementary Figure 1A) and
were completely devoid of Fut4 and Fut9 gene expression
(Supplementary Figure 1B). Therefore, we considered MC38 as an
ideal candidate cell line for screening the functionality of the designed
Fut4 and Fut9 gene targeting gRNAs in vitro. Expression of Lewisx
was used as a collective readout for efficient induction of Fut4 or
Fut9 gene transcription and subsequent fucosyltransferase function.
Specifically, we examined the efficiency of the selected gRNA
sequences by co-transfecting MC38 cells with the Sp-dCas9-VR plas-
mid and one of the Fut4- or Fut9-targeting gRNA constructs
(Supplementary Table I). Two days after transfection, MC38 cells
were harvested and stained with an anti-Lewisx specific antibody
(clone P12) and the expression levels of cell surface Lewisx were
assessed by flow cytometric analysis (Supplementary Figure 1E).
Interestingly, MC38 cells that were transiently transfected with only
one of the two Fut4-targeting gRNAs (gRNA#4-1 or gRNA#4-2) or
the Fut9-targeting gRNAs (gRNA#9-1 or gRNA#9-2) displayed high-
er expression of Lewisx compared to MC38 cells transfected with Sp-
dCas9-VPR construct only (control). This implied that all our four
selected gRNAs were functional by means of promoter targeting and
that the efficiency of the CRISPR-dCas9-VPR system was successfully
translated into functional glycosyltransferases. In addition, we further
confirmed the functionality of the designed gRNA sequences by tran-
siently transfecting two different murine cancer cell lines negative for
Fut4 and Fut9 gene expression, Panc02 (pancreatic cancer) and LL/2
(Lewis Lung cancer) cells (Supplementary Figure 1C, D, F, G), follow-
ing exactly the same procedure as mentioned above and again
obtained de novo expression of Lewisx. The small discrepancies
observed in the efficiency of Lewisx induction, though, clearly indicate
the sequence-specific and cell line-dependent variation of the different
gRNAs used in our experiments. As gRNA#4-1 and gRNA#9-1
exhibited slightly higher targeting efficiencies in MC38 cells specific-
ally, using Lewisx expression as a final readout, we proceeded with
only these two single gRNAs for the remainder of our studies.
Our next step was to generate stable MC38-FUT4 or MC38-
FUT9 expressing cells and to evaluate possible changes in their cell
surface glycosylation profiles. In this case and compared to MC38-
MOCK cells, we observed >200-fold induction of the Fut4 mRNA
levels in MC38-FUT4 cells (Figure 2A) and >300-fold induction of
the Fut9 mRNA levels in MC38-FUT9 cells (Figure 2B), respect-
ively. Also, no induction of Fut9 gene expression was observed in
MC38-FUT4 cells and vice versa, thus showing the specificity of our
gRNAs and the CRISPR-dCas9-VPR system. Subsequently, stably-
transfected MC38 glycovariants were stained with an anti-Lewisx
specific antibody and the expression levels of cell surface Lewisx
were assessed using flow cytometry. Consistent with the increased
mRNA levels of the Fut4 and the Fut9 genes upon gene activation,
significant neo-expression of the Lewisx epitope could be detected
on the cell surface of both MC38-FUT4 (>100-fold induction) and
MC38-FUT9 cells (>150-fold induction), but not on the MC38-
MOCK cells (Figure 2C, E). These results indicate that besides tran-
scriptional gene activation, the CRISPR-dCas9-VPR system can be
directly coupled to physiologically relevant fucosyltransferase func-
tion, represented in this case by the biosynthesis and the elevated
cell surface expression of the Lewisx determinant in MC38-FUT4
and MC38-FUT9 glycovariants.
In order to confirm the specificity of the de novo Lewisx expres-
sion, cells were treated with different concentrations of the fucosyl-
transferase inhibitor 2F-peracetyl fucose (2F-PF) (Rillahan et al.
2012) and stained with the anti-Lewisx antibody. As expected,
expression of Lewisx gradually decreased on the surface of MC38-
FUT4 and MC38-FUT9 cells upon escalating doses of 2F-PF, with a
maximal effect observed at an inhibitor concentration of 100 μg/mL
(Figure 2D). Noticeably, Lewisx expression was totally absent on
MC38-MOCK cells, irrespective of the inhibitor treatment or not.
Besides Lewisx, no other fucosylated type I or type II Lewis antigens
(structurally related to Lewisx) could be recorded on the surface of
MC38 glycovariants (Figure 2F), confirming that transcriptional
activation of the Fut4 and Fut9 genes in MC38 cells specifically
results in increased levels of the Lewisx epitope only.
During our studies, we noticed that in MC38-FUT4 cells specific-
ally, expression of the Lewisx antigen gradually decreased over time.
This prompted us to examine the Fut4 and Fut9 gene expression levels
at different time points in MC38 cells. Interestingly, elevated mRNA
levels of the Fut4 gene (compared to MC38-MOCK cells) could be
observed only within the first 48 h after isolation of the Lewisx+ cell
population in MC38-FUT4 cells, followed by a dramatic decrease 96 h
later (Supplementary Figure 2A). This could probably explain the sub-
sequent decrease in cell-surface expression of Lewisx 96 h after the ini-
tial enrichment (Supplementary Figure 2C). On the contrary, mRNA
levels of the Fut9 gene and the expression of Lewisx in MC38-FUT9
cells remained stable over time, since we were able to detect exactly the
same expression pattern even 30 days after sorting of the Lewisx+ cell
population in these cells (Supplementary Figure 2B, C). Noticeably, the
gradual decrease in Lewisx neo-expression in MC38-FUT4 cells (with
both a Lewisx+ and a Lewisx- cell population being present at the same
time) was not accompanied by a subsequent increase in the cell surface
levels of other Lewis antigens (Supplementary Figure 2D), limiting the
possibility of Lewisx masking by other fucosyltransferases. Thus, loss
of expression of the Fut4 gene, in contrast to the Fut9 gene, suggests
that the expression of these specific fucosyltransferase genes may be
differentially regulated in our cells. However, whether this loss of
FUT4 is really due to unknown genetic or epigenetic factors influencing
fucosyltransferase-specific gene expression levels in the context of colo-
rectal cancer remains to be elucidated by future studies.
The Lewisx antigen is mainly carried by N-linked
glycans and influences α2-3 sialylation in MC38-FUT4
and MC38-FUT9 cells
After the generation and characterization of MC38 glyco-engineered
cell lines, we wondered whether induction of the Fut4 and Fut9 genes,
would affect the global cell surface glycosylation patterns of MC38
cells. For this purpose, we exploited a number of commonly used
fucose- and sialic acid-recognizing plant lectins and assessed their
binding to our MC38 glycovariants using flow cytometry (Figure 3A–
F). As expected, we observed significantly higher binding of LTA
(Lotus Tetragonolobus Agglutinin with specificity for terminal α1-3
fucosylation) to MC38-FUT4 and MC38-FUT9 cells compared to
MC38-MOCK cells, which was completely reversed upon treatment
of the cells with 2F-PF, confirming the presence of Lewisx on these
cells. However, no statistically significant differences in UEA-I (Ulex
Europaeus Agglutinin-I recognizing terminal α1-2 fucosylation) or
AAL binding (Aleuria Aurantia Lectin with specificity for core
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fucosylation and terminal α1-3 fucosylation) could be discerned
among the examined MC38 cell lines, although a trend of decreased
AAL binding to MC38-FUT4 and MC38-FUT9 cells was noted in the
absence of 2F-PF treatment. At this point, due to the overlapping spe-
cificity of AAL for core fucosylation and terminal α1-3 fucosylation,
we could not draw any conclusions from the AAL binding experi-
ments. To our surprise, MC38-FUT4 and MC38-FUT9 cells dis-
played decreased binding of MAL-I (Maackia Amurensis Lectin-I
recognizing α2-3 sialylation on N-glycans), while MAL-II (Maackia
Amurensis Lectin-II with specificity for α2-3 sialylation on O-glycans)
and SNA (Sambucus Nigra Agglutinin with specificity for α2-6 sialy-
lation) displayed equal binding to all glycovariants. In addition,
MAL-I binding to MC38-FUT4 and MC38-FUT9 cells could be res-
cued upon treatment of the cells with 2F-PF.
Based on these results, we hypothesized that the Lewisx trisac-
charide might be carried by N-linked glycan structures on the sur-
face of MC38-FUT4 and MC38-FUT9 cells, thereby competing with
α2-3 sialylation on N-glycans in these cells. Therefore, we treated
MC38 glycovariants with different inhibitors of glycosylation and
we examined changes in the surface expression of Lewisx
(Figure 3G, H). Interestingly, Lewisx expression in both MC38-
FUT4 and MC38-FUT9 cells was almost completely abrogated
upon treatment with Kifunensine (N-glycosylation inhibitor), pro-
viding strong evidence that the Lewisx epitope is predominantly car-
ried by N-linked glycans. Of note, the decrease in Lewisx expression
due to Kifunensine treatment was comparable to the one observed
after treatment of MC38 glycovariants with the general fucosyl-
transferase inhibitor, 2F-PF. Nevertheless, treatment of MC38
Fig. 2. Specific neo-expression of the Lewisx epitope on the surface of MC38-FUT4 and MC38-FUT9 glycovariants generated by the CRISPR-dCas9-VPR technol-
ogy. (A and B) RT-PCR-based assessment of the Fut4 and Fut9 mRNA levels in MC38-glycovariants generated upon transcriptional gene activation using the
CRISPR-dCas9-VPR system. Expression was normalized to the housekeeping gene GAPDH (M. musculus). Statistical differences relative to MC38-MOCK cells
are depicted. (C) Flow cytometric analysis of the Lewisx antigen expression on the surface of MC38 glycovariants using a mouse anti-Lewisx monoclonal anti-
body (clone P12). Dotted lines represent staining with the secondary antibody alone, whereas solid lines represent the Lewisx staining. Histograms representa-
tive of at least three independent experiments are shown. (D) MC38-glycovariants were cultured in vitro for 48 h with different concentrations of the
fucosyltransferase inhibitor 2F-peracetyl fucose (2F-PF). Expression levels of Lewisx were assessed by flow cytometry. (E) Expression of Lewisx on the surface of
MC38-FUT4 and MC38-FUT9 cells is abrogated after treatment of cells with 100 μg/mL of the fucosyltransferase inhibitor 2F-peracetyl fucose (2F-PF). Mean fluor-
escent intensities of three independent experiments were normalized to the binding of the secondary antibody alone. (F) Expression of other known type I and
type II Lewis antigens (structurally related to Lewisx) on the cell-surface of MC38-glycovariants, as analyzed by flow cytometry. Mean fluorescent intensities of
three independent experiments were normalized to the binding of the secondary antibody alone. Statistical significance was determined by a Student’s
unpaired t test with Welch’s correction (**P < 0.01).
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glycovariant cells with either benzyl-α-GalNAc (O-glycosylation
inhibitor) or PPMP (glucosphingolipid synthesis inhibitor) revealed
unique differences in the substrate specificity of the FUT4 and FUT9
enzymes, as Lewisx appeared to be present, although to a lesser
extent, also on O-glycans and glycosphingolipids in MC38-FUT4
and MC38-FUT9 cells, respectively.
N-glycoprofiling of MC38 engineered cells reveals
potent changes in their N-glycome composition
Given that the Lewisx antigen is mainly carried by N-linked glycans
in MC38-FUT4 and MC38-FUT9 cells, we proceeded to detailed
mass spectrometric N-glycoprofiling aimed at the identification of
FUT4-, FUT9- or in general, Lewisx-specific alterations in the N-
glycan composition of these cells. N-glycans released from whole
MC38 cells with the use of PNGase F were labeled with procaina-
mide and subsequently analyzed by HILIC-(U)HPLC-FLR-ESI-MS.
All our MC38 glycosylation variants expressed core-fucosylated
(fucose residue added in an α1-6 linkage to the innermost GlcNAc
of the oligosaccharide core) N-glycans, as indicated by the AAL
binding (Figure 3C). Nevertheless, the N-glycoprofiling analysis
revealed that distinct di- or tri-fucosylated N-linked glycans bearing
both core-fucose and the Lewisx antigen (fucose residue added in an
α1-3 linkage to distal GlcNAc residues of the oligosaccharide chain)
were detected in MC38-FUT4 and MC38-FUT9 cells only, but not
in MC38-MOCK cells (Figure 4A, B, C), validating our previous
characterization of MC38-glycovariants using either the anti-Lewisx
specific antibody or the LTA plant lectin. Furthermore, we assessed
Fig. 3. Lewisx expressed on the surface of both MC38-FUT4 and MC38-FUT9 cells is mainly carried by N-linked glycans. (A–F) MC38-glycovariants, cultured for
48 h in the presence or absence of the fucosyltransferase inhibitor 2F-peracetyl fucose (2F-PF), were incubated for 30min at 37°C with the indicated biotinylated
plant lectins. The levels of antennary α1-3 fucosylation (LTA binding) (A), antennary α1-2 fucosylation (UEA-I binding) (B), core-fucosylation/ α1-3 fucosylation
(AAL binding) (C), α2-3 sialylation on N-linked glycans (MAL-I binding) (D), α2-3 sialylation on O-linked glycans (MAA-II binding) (E) and α2-6 sialylation (SNA
binding) (F) were examined by flow cytometry. (G and H) MC38-FUT4 (G) and MC38-FUT9 (H) cells were treated with different inhibitors of glycosylation for 48 h
and changes in the cell-surface expression of Lewisx were assessed by flow cytometry. Relative binding (A–F) or expression (G, H) represents the mean fluores-
cent intensities of three independent experiments after normalization to the binding of the corresponding secondary antibody alone. Statistical differences rela-
tive to the untreated condition are shown in G and H. Statistical significance was determined by a Student’s unpaired t test with Welch’s correction (*P < 0.05,
**P < 0.01, ***P < 0.001).
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the relative abundance of the identified N-linked glycans
(Supplementary Table II) for each cell line separately, focusing on
specific traits related to N-glycosylation (Table I), and classified the
possible glycan compositions according to the paper by Holst et al.
(2016). In agreement with our earlier observations, MC38-FUT4
and MC38-FUT9 cells displayed a higher relative abundance of di-
or tri-fucosylated N-linked glycans compared to MC38-MOCK cells
(Figure 5A), highlighting once again the presence of Lewisx in these
cells (representative example of the MS/MS analysis of MC38-FUT9
cells is provided as Supplementary Table III). Also, a decrease in the
relative abundance of mono-fucosylated glycans (corresponding to
core-fucosylation) was observed in MC38-FUT4 and MC38-FUT9
cells compared to MC38-MOCK cells, providing an explanation for
the reduced AAL binding obtained before. Additionally, the
decreased abundance of sialylated glycans (especially the di- and tri-
sialylated ones) in MC38-FUT4 and MC38-FUT9 cells (Figure 5B)
was consistent with the reduced MAL-I binding to these cells in
comparison to MC38-MOCK cells. Therefore, these results imply
that the biosynthesis and increased expression of Lewisx have a
negative impact both on core-fucosylation and on the N-linked sialic
acids.
Next, we explored potential differences among the MC38-
glycovariants in terms of N-glycan antennarity and specific glycan
subtypes. Interestingly, compared to MC38-MOCK cells, MC38-
FUT4 and MC38-FUT9 cells were characterized by a higher relative
abundance of di- and tri-antennary N-linked glycans and by lower
relative abundance of tetra- or tetra-/poly- N-linked glycans
(Figure 5C). In addition, a small percentage of pure poly-antennary
N-linked glycans could be identified only in MC38-FUT4 and MC38-
FUT9 cells and not in the MC38-MOCK cell line. Furthermore, a
switch in the balance of the known N-glycan types among the exam-
ined MC38 cells could be discerned, with MC38-FUT4 and MC38-
Fig. 4. N-glycoprofiling of MC38-glycovariants using HILIC-(U)HPLC-FLR-ESI-MS. FLR chromatograms (10–45min) corresponding to MC38-MOCK (A), MC38-
FUT4 (B) and MC38-FUT9 (C) cells. Representative examples of di- or tri-fucosylated glycans bearing the Lewisx antigen are depicted. The most abundant peaks
of the FLR chromatograms represent the high-mannose N-glycans (H5N2/Man5, H6N2/Man6, H7N2/Man7, H8N2/Man8, H9N2/Man9) identified through our ana-
lysis. H = hexose (Hex); N = N-acetylhexosamine (HexNAc); F = fucose (Fuc); S = sialic/neuraminic acid (NeuAc).
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FUT9 cells exhibiting a higher relative abundance of complex and a
lower relative abundance of high-mannose or hybrid N-glycans com-
pared to MC38-MOCK cells (Figure 5D). Collectively, these findings
indicate that the emergence of Lewisx on MC38-FUT4 and MC38-
FUT9 cells induces potent changes in the cancer cell N-glycome, influ-
encing antennarity and the respective glycan subtypes.
Finally, we were able to pinpoint a number of FUT4 and FUT9-
specific N-glycan compositions through our analysis (Table II). For
example, the composition H7N6F3 appeared only in the MC38-
FUT9 cells and not in the MC38-MOCK or MC38-FUT4, while the
composition H5N4F3S1 seemed to be exclusively expressed in the
MC38-FUT4 cells. Together our data indicate that FUT4 and FUT9
may have overlapping, yet also unique biosynthetic properties
regarding the modification of the substrate N-glycome in tumor
cells.
Lewisx antigen neo-expression is functionally relevant
and can be recognized by designated lectin receptors
After our thorough examination of the N-glycome of the MC38-
FUT4 and MC38-FUT9 glycovariant cell lines, we next determined
the functional relevance of cell surface Lewisx and evaluated the
binding of specific C-type lectin receptors (CLRs) to our MC38 gly-
covariants in vitro. For this purpose, we used human DC-SIGN
(hDC-SIGN) (van Gisbergen et al. 2005) and mouse MGL-1
(mMGL-1) (Montero-Barrera et al. 2015), as these CLRs are well-
known Lewisx-recognizing receptors that are physiologically
expressed on antigen-presenting cells, such as dendritic cells and
macrophages. As a negative control, we chose mouse MGL-2
(mMGL-2) (Singh et al. 2009), taking advantage of its lack of speci-
ficity for the Lewisx determinant. Compared to the MC38-MOCK
cells, a significant increase in the binding of hDC-SIGN (Figure 6A)
and mMGL-1 (Figure 6B), but not mMGL-2 (Figure 6C), could be
observed to MC38-FUT4 and MC38-FUT9 cells. Since there was no
CLR binding to MC38-MOCK cells lacking Lewisx and the binding
was completely lost upon treatment of MC38-FUT4 and MC38-
FUT9 cells with 2F-PF, we concluded that the receptor–ligand inter-
actions were CLR-specific and Lewisx-mediated.
Taken together, our results signify that the Lewisx determinant
synthesized by the FUT4 and FUT9 enzymes following CRISPR-
dCas9-VPR-induced gene activation is expressed on the cell-surface
in a physiological manner, thus maintaining the full range of its
functional and biologically relevant properties.
Discussion
Since the initial discovery of clustered regularly interspaced short
palindromic repeats (CRISPR) as the adaptive immune system of
bacteria and archaea (Wiedenheft et al. 2012), the CRISPR-Cas9
system has been rapidly transformed to a powerful genome-
engineering tool with various research applications, including gene
editing (gene knock out/in) and gene expression programming (tran-
scriptional gene activation/suppression) among others. The greatest
advantage of this system is that the Cas9 nuclease (wild type or
deactivated) can be directed to virtually everywhere in the genome
with the use of short guide RNAs which, based on DNA sequence
complementarity, specifically target the genomic region of interest
(Hsu et al. 2014).
Undoubtedly, research investigations focused on protein and
lipid glycosylation can be vastly facilitated by the availability of the
CRISPR-Cas9 technology. Besides the direct glycan analysis techni-
ques that have been developed and mainly used so far, the glycosyla-
tion machinery within the cells and various functional properties of
the glycome can be now further explored through the genetic dissec-
tion of distinct glycan biosynthetic pathways. For example, a
GlycoCRISPR resource became recently available (Narimatsu et al.
2018), including a validated gRNA library for CRISPR-Cas9 target-
ing of the human glycosyltransferase genome and enabling potential
gene knock-out applications suitable for 167 human enzymes
involved in glycan biosynthesis.
In the present study, we exploited the CRISPR-dCas9-VPR sys-
tem for transcriptional activation of certain α1-3 fucosyltransferase
genes, Fut4 (Giordano et al. 2015) and Fut9 (Auslander et al. 2017),
playing a major role in colorectal cancer pathogenesis. According to
our findings, transcriptional activation of the Fut4 and Fut9 genes in
MC38 cells resulted in specific neo-expression of the Lewisx antigen
on the cell surface. With this, we concluded that the CRISPR-dCas9-
VPR-mediated transcriptional gene activation of FUT4 and FUT9 in
MC38 cells can be reliably linked to the tumor-associated fucosyl-
transferase function, with Lewisx emerging as the main fucosylated
epitope that these enzymes synthesize in common in the context of
colorectal cancer.
Regarding the substrate specificity, it is known that FUT9 prefer-
entially fucosylates the GlcNAc residue at the distal lactosamine unit
of the polylactosamine chain, whereas FUT4 transfers a fucose to
the GlcNAc residue at the inner lactosamine unit (Nishihara et al.
1999). However, the preferred carrier molecules of Lewisx, synthe-
sized by FUT4 and FUT9 in colorectal cancer cells, have been
scarcely studied so far. In our MC38 model system, Lewisx was pre-
dominantly carried by N-linked glycans in both MC38-FUT4 and
Table I. Formulas used for calculation of the relative abundance of
specific traits defining the N-glycome of MC38-glycovariants,
including fucosylation, sialylation, antennarity and glycan subtype
Examined traits Calculation
Fucosylation
Mono- ∑(Fuc = 1)
Di- ∑(Fuc = 2)
Tri- ∑(Fuc = 3)
Sialylation
Mono- ∑(NeuAc = 1)
Di- ∑(NeuAc = 2)
Tri- ∑(NeuAc = 3)
Antennarity
Mono- ∑(HexNAc ≤ 3)
Di- ∑(Hex = 5 and HexNAc = 4)
Di/Tri- ∑(Hex ≤ 5 and HexNAc = 5)
Tri- ∑(Hex = 6 and HexNAc = 5)
Tri/tetra- ∑(Hex ≤ 6 and HexNAc = 6)
Tetra- ∑(Hex = 7 and HexNAc = 6)
Tetra/poly- ∑(Hex ≤ 7 and HexNAc = 7)
Poly- ∑(Hex > 7 and HexNAc > 6)
Glycan subtype
High-mannose (HighMan) ∑(Hex4-10HexNAc2)
Pauci-mannosidic (PauciMan) ∑(Hex1-3HexNAc2)
Hybrid ∑(Hex-HexNAc > 2)
Complex ∑(Hex-HexNAc ≤ 1)
The number of N-glycans matching the provided formulas was trans-
formed into a relative abundance by dividing it to the total number of N-gly-
cans identified for each cell line and multiplying it with 100%. Hex = hexose,
H; HexNAc = N-acetylhexosamine, N; Fuc = fucose, F; NeuAc = sialic/neur-
aminic acid, S.
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MC38-FUT9 cells. Nevertheless, critical differences in the substrate
specificity of the FUT4 and the FUT9 enzymes were also detected in
our analysis, since O-glycans and glycosphingolipids appeared to be
the secondary preferential glycan carriers of Lewisx in MC38-FUT4
and MC38-FUT9 cells, respectively (Nishihara et al. 2003,
Sperandio et al. 2009).
Defining the cancer-specific biosynthetic properties of FUT4 and
FUT9 is fundamental for the interpretation of the biological functions
that these enzymes exert within a tumor cell. Strikingly, N- and O-
glycans, as well as glycosphingolipids, have been associated with dif-
ferent functional properties during malignant cell transformation or
metastasis (Oliveira-Ferrer et al. 2017). For example, N-glycans regu-
late the protein conformation as well as the intracellular signaling
properties of tumor-associated growth factor receptors, such as the
epidermal growth factor receptor (EGFR) and the transforming
growth factor β (TGF-β) receptor (Takahashi et al. 2016). Therefore,
N-glycans have been recently proposed as therapeutic targets in colo-
rectal cancer (de Freitas and Morgado-Diaz 2016). O-glycans have
specialized functions in cell adhesion and lipid metabolism (Chia
et al. 2016), whereas glycosphingolipids play a major role in anti-
cancer drug resistance (Gouaze-Andersson and Cabot 2006) and have
been implicated in the maintenance of cancer stemness (Liang et al.
2017).
More specifically, we demonstrate here that de novo synthesis of
the fucosylated Lewisx antigen by FUT4 and FUT9 leads to potent
alterations in the N-glycome of colorectal cancer cells, with a negative
impact exerted on core-fucosylation and the α2-3 sialylation levels.
This observation highlights existing monosaccharide-, enzyme- and
site-specific antagonistic effects occurring during the early stages of
N-glycan biosynthesis, the dynamics of which are commonly missed
or undermined due to the lack of techniques that are sensitive enough
for detection of real-time changes in the cancer cell glycome. In more
detail, changes in the N-glycan composition of cancer cells have been
shown to affect the subsequent interaction with immune cells (Nardy
et al. 2016). For instance, hypersialylated tumor cells can engage dif-
ferent Siglec (sialic acid-binding immunoglobulin-type lectins) recep-
tors expressed on myelomonocytic cells and inhibit successful
immunosurveillance, depending on the stage of tumor growth and the
surrounding microenvironment (Laubli et al. 2014). However, it is
still unknown whether increased expression of FUT4 and FUT9,
Fig. 5. Relative abundance of distinct N-linked glycans in MC38-glycovariants identified by HILIC-(U)HPLC-FLR-ESI-MS. The possible N-glycan compositions
were classified based on the specific traits examined, such as fucosylation (A), sialylation (B), antennarity (C) and glycan subtype (D), and the relative abundance
was calculated for each cell line as indicated in Table I. “Other” represents the N-linked glycan compositions that could not be assigned according to the formu-
las provided in Table I.
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influencing the abundance of α2-3-linked sialic acids on N-glycans, is
associated with decreased Siglec binding to colorectal cancer cells and
modulation of the anti-tumor immune response in vivo. Conversely,
the FUT4- and FUT9-mediated synthesis of DC-SIGN and MGL-1
ligands containing the Lewisx epitope hints to potential implication of
these enzymes in the induction of an immunosuppressive tumor
microenvironment in colorectal cancer. This is supported by the fact
that DC-SIGN binding to Lewis antigens overexpressed by cancer
cells, results in induction of T helper 2 (Th2) and regulatory T (Treg)
cells, decreased activity of natural killer (NK) cells and increased pro-
duction of anti-inflammatory cytokines, such as interleukin-10 (IL-
10) (Rodríguez et al. 2018). Although the exact involvement of
MGL-1 in the tumor growth remains elusive, expression of MGL-1
by macrophages has been associated with increased production of IL-
10 and acquisition of an anti-inflammatory role in a mouse model of
experimental colitis (Saba et al. 2009).
Additionally, the induction of complex N-glycan synthesis in
MC38 cells upon FUT4 and FUT9 induction raises a possible role
for these fucosyltransferases in the metabolic control of colorectal
cancer cells. So far, the contribution of complex N-glycans to the
altered metabolic status of cancer cells, especially through sensitiza-
tion to different growth factors, has been merely linked to the
expression of Mgat5 (Golgi beta1,6N-acetylglucosaminyltransferase
V) (Mendelsohn et al. 2007), although more glycosyltransferases
might be directly or indirectly involved in this process (Munkley and
Elliott 2016). Moreover, LacNAc stretches on complex N-glycans
are major ligands for Galectins involved in tumorigenesis, such as
Galectin-1, -3 and -8 (Patnaik et al. 2006). Nevertheless, whether
the observed changes in N-glycan antennarity and abundance of
complex N-glycans in MC38-FUT4 and MC38-FUT9 cells influence
the metabolic or Galectin binding properties (Chou et al. 2018) of
colorectal cancer cells, requires further investigation.
In summary, we here show that application of the CRISPR-
dCas9-VPR technology to augment glycosyltransferase expression in
primary cells or cell lines can provide a better insight into potential
alterations occurring during malignant cell transformation, and
thus, unravel multiple aspects related to the structural or functional
properties of the mammalian glycome in health and disease.
Materials and methods
pX330-Delta_Puro cloning
The parental pX330 sgRNA Cas9 expression vector from the Zhang
lab was obtained from Addgene (ID42230, Addgene, Cambridge,
USA). The Puromycin resistance cassette from pX260 (Zhang lab,
ID42229, Addgene) was PCR amplified with Phusion High Fidelity
polymerase (New England BioLabs, Massachusetts, USA) using for-
ward primer: 5′GGTCGCCCGACGCCCTTACGTCCAGCCAAG
CTTAG3′, and reverse primer: 5′TCACTGAGGCCGCCCCGTAC
TATGGTTGCTTTGAC3′ (Sigma Aldrich, Missouri, USA). The PCR
product encoding the Puromycin marker was cloned into the pX330
vector after backbone linearization using two neighboring SmaI
restriction sites (New England BioLabs) and InFusion cloning
(Clontech, California, USA). Next, the Cas9 coding sequence was
removed from the vector backbone by NcoI and EcoRI (New
England BioLabs) digests. A linker consisting of hybridized oligonu-
cleotides was cloned into the NcoI and EcoRI sites to circularize the
vector using InFusion cloning. Oligonucleotide sequences used were,
sense: 5′ATCGCTATTACCATGGAACAATGAGTCTGCATCAAG3′,
anti-sense: 5′CGAGCTCTAGGAATTCTTGATGCAGACTCATTGTT
C3′ (Sigma Aldrich).
Table II. List of possible N-linked glycans differing among the
examined MC38-glycovariants.
Possible composition MC38-MOCK MC38-FUT4 MC38-FUT9
Neutral
H3N6 − + +
H4N8 − − +
H6N3 + + −
H6N4 + − +
H6N5 − − +
H6N7 + − −
H7N3 + + −
H7N4 + − −
H7N5 + − −
H7N8 − + −
H8N7 − − +
H9N3 − − +
H9N8 − + −
H10N2 + − +
Fucosylated
H3N9F1 − + −
H5N2F1 − + +
H5N3F1 − + +
H5N5F1 − + −
H7N6F1 + + −
H9N5F1 + − −
H3N3F2 − + +
H4N3F2 − + +
H4N4F2 − + +
H4N5F2 − + +
H4N6F2 + − −
H5N4F2 − + +
H4N4F3 − + +
H4N5F3 − + +
H5N4F3 − + +
H5N5F3 − + −
H7N6F3 − − +
Sialylated
H3N4S1 + − −
H4N3S1 − + +
H4N4S1 − + +
H4N5S1 − + +
H7N6S1 + − −
H4N4S2 + − −
H4N5S2 − + +
H5N5S2 − + −
H7N6S2 + − +
H5N5S3 − − +
Mixed
H4N3F1S1 + − −
H4N4F2S1 − + +
H5N4F2S1 − + +
H5N4F3S1 − + −
H5N5F1S1 − + −
H7N6F1S1 + − +
H8N5F1S1 + − −
H5N4F1S2 + + −
H5N4F3S2 − − +
H6N5F1S2 + − −
H7N5F1S2 + − +
H7N7F1S2 − − +
H6N5F1S3 + − −
H8N7F1S4 − − +
N-glycans unique to only one of our glycovariant cell lines are highlighted in
bold; (+) indicates presence, (–) indicates absence. Hex = hexose, H; HexNAc = N-
acetylhexosamine, N; Fuc = fucose, F; NeuAc = sialic/neuraminic acid, S.
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gRNA design and cloning
As previously described (Chavez et al. 2015), the principle behind
Cas9-mediated transcriptional programming is that one or multiple
gRNA sequences specifically target the promoter region of the gene
of interest in close proximity to the transcriptional start site, result-
ing in direct recruitment of the catalytically inactive dCas9 nuclease
to this site. The subsequent interaction between the VPR (VP64-
p65-Rta) tripartite activation domain and RNA polymerase II and/
or other transcription factors drives the induction of expression of
the (glyco)gene of interest (Figure 1A). For this reason, the
Eukaryotic Promoter Database (EPD) (https://epd.vital-it.ch/index.
php) was used for selecting the promoter regions of the murine Fut4
and Fut9 genes. 20-nucleotide gRNAs sequences complementary to
the promoter of each target fucosyltransferase gene were designed
and validated with the E-CRISP (http://www.e-crisp.org/E-CRISP/)
and the CRISPR design prediction tools (http://crispr.mit.edu/),
respectively (Supplementary Table I). The Basic Local Alignment
Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and
the transcription factor binding-site prediction tool (Tfsitescan)
(http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl) were exploited for
quality control of the selected gRNAs and to avoid interference with
major transcription factor-binding sites (Figure 1B). Selected gRNAs
(Supplementary Table I) were ordered (Invitrogen, California, USA)
and cloned afterwards into the pX330-Delta_Puro expression vec-
tor, as described by Ran et al. (2013). Finally, the SP-dCas9-VPR
plasmid from the Church lab (ID63798, Addgene) was used for
expression of the dCas9-VPR protein.
Cell culture and transfections
Wild type MC38 cells (murine colon carcinoma), Panc02 (mouse pan-
creatic ductal adenocarcinoma) (gift from Prof. Dr. M. van Egmond,
Amsterdam UMC, Vrije Universiteit Amsterdam, Dept. of Surgery and
Molecular Cell Biology and Immunology, Cancer Center Amsterdam),
LL/2 (Lewis lung carcinoma) (gift from Prof. Dr. T. Freire, UdelaR,
Montevideo, Uruguay) and glyco-engineered cell lines were maintained
in high glucose Dulbecco’s Modified Eagle’s Medium (Gibco, Life
Technologies, California, USA) supplemented with 10% FBS premium
(Biowest, Nuaillé France) and penicillin/streptomycin (Lonza, Bazel,
Switzerland). Cells were maintained at 37°C and 5% CO2 in a humidi-
fied incubator and tested for mycoplasma infection monthly. Cells
were transfected in 24-well plates seeded with 50.000 cells per well.
400 ng of the SP-dCas9-VPR-expressing plasmid plus 80 ng of the
empty (MC38-MOCK cells) or 80 ng of the FUT4/FUT9 gRNA-
expressing PX330-Puro_Delta plasmid (MC38-FUT4/FUT9 cells) were
delivered simultaneously to the corresponding wells (protocol adapted
from Chavez et al.) together with Lipofectamine LTX (Invitrogen),
according to manufacturer’s instructions. During transient transfec-
tions, cells were grown for 48 h before being assayed by flow cytome-
try. Stable cell lines were selected with 6 μg/mL Puromycin (Sigma
Aldrich) for expression of the corresponding gRNA construct, which
was applied to the cells 48 h post-transfection.
Enrichment of Lewisx+ MC38 cells
Manual cell separation (MACS) with the use of anti-CD15 (Lewisx)
microbeads (Miltenyi Biotec, San Diego, USA) was performed
according to manufacturer’s instructions to enrich for the Lewisx+
MC38-FUT4 and MC38-FUT9 glyco-engineered cells 10 days after
initial transfection. From this point and due to deviation in the sta-
bility of the Fut4 gene expression levels, enrichment of the Lewisx+
fraction of MC38-FUT4 cells specifically was conducted every 2–3
days in order to maintain Lewisx neo-expression in the MC38-FUT4
until the completion of our study. MC38-FUT9 were stable through-
out our analysis and did not require any further enrichment steps.
qRT-PCR analysis
MC38, Panc02 and LL/2 cell-lysis and mRNA isolation was per-
formed with the mRNA capture kit (Roche, Bazel, Switzerland) and
cDNA synthesis was performed using the Reverse Transcription
System Kit (Promega, Wisconsin, USA), according to manufacturer’s
instructions. Synthesized cDNA samples together with the KAPA
SYBR® FAST Universal 2X qPCR Master Mix and specific qPCR pri-
mers were utilized for each qRT-PCR reaction. Precisely, qPCR pri-
mer sequences used for cDNA amplification were as follows: GAPDH
forward primer: CCTGCACCACCAACTGCTTAG; GAPDH reverse
primer: CATGGACTGTGGTCATGAGCC; FUT4 forward primer:
CAGCCTGCGCTTCAACATC; FUT4 reverse primer: CGCCTTAT
CCGTGCGTTCT; FUT9 forward primer: ATCCAAGTGCCTTAT
GGCTTCT; FUT9 reverse primer: TGCTCAGGGTTCCAGTTACT
CA. qRT-PCR for individual genes was ran and analyzed on the
CFX96 Real-Time PCR Detection System (BIORAD, California,
USA), with all target gene expression levels normalized to GAPDH
(M. Musculus) mRNA levels.
Fig. 6. Binding of C-type lectin receptors to MC38-glycovariants. MC38 cells, cultured for 48 h in the presence or absence of the fucosyltransferase inhibitor 2F-
peracetyl fucose (2F-PF), were incubated for 30min at 37°C with human DC-SIGN-Fc (DC-SIGN) (A), mouse MGL-1-Fc (MGL-1) (B) or mouse MGL-2-Fc (MGL-2)
(C) and lectin binding was assessed by flow cytometric analysis. Relative binding represents the mean fluorescent intensities of three independent experiments
after normalization to the binding of the secondary antibody alone. Statistical significance was determined by a Student’s unpaired t test with Welch’s correction
(***P < 0.001).
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Flow cytometry
The primary antibodies used were: anti-Lewisa (clone T174, Calbiochem,
San Diego, USA), anti-Lewisb (clone T218, Calbiochem), anti-Lewisx
(clone P12, Calbiochem), anti-Lewisy (clone F3, Abcam, Cambridge,
United Kingdom), anti-sialyl-Lewisx (clone CSLEX, BD Pharmingen, San
Jose, USA) and anti-CD65s (clone VIM-2, LabNed, the Netherlands).
The biotinylated lectins used were: LTA (Lotus Tetragonolobus
Agglutinin α-1,3-linked fucose), UEA-I (Ulex Europaeus Agglutinin-I, α-
1,2-linked fucose), AAL (Aleuria Aurantia Lectin, α-1,6-linked and α-
1,3-linked fucose), MAL-I (Maackia Amurensis Lectin-I, α-2,3-linked
sialic acid residues on N-glycans), MAL-II (Maackia Amurensis Lectin-II,
α-2,3-linked sialic acid residues on O-glycans) and SNA (Sambucus
Nigra Agglutinin, α-2,6-linked sialic acid residues), all ordered from
Vector Labs (Burlingame, USA). The plant lectin specificity provided
above was confirmed by the Functional Glycomics Database (CFG):
http://www.functionalglycomics.org/. The C-type lectin-Fc constructs
were generated as previously described (Appelmelk et al. 2003) (Singh
et al. 2009).
Cells were harvested, washed and resuspended in phosphate buf-
fered saline (PBS) or Hank’s balanced salt solution (HBSS) (Gibco,
Life Technologies) containing 0.5% bovine serum albumin (BSA) at
1 × 106 cells/mL. 50.000 cells were added to each well of a 96-well
V-bottom plate and incubated with 5 μg/mL of the respective pri-
mary antibodies, biotinylated lectins or 10 μg/mL of the C-type lec-
tin-Fc constructs for 30min at 4°C or 37°C, respectively. Cells were
washed and resuspended in 50 μL PBS or HBSS (0.5% BSA) con-
taining the corresponding secondary reagents and incubated for
30min at 37°C. Goat anti-mouse IgG FITC was used for anti-
Lewisa (Jackson Labs, California, USA) and goat anti-mouse IgM
FITC (Jackson Labs, USA) was used for the other primary anti-
bodies. Streptavidin-APC (Biolegend, California, USA) was used to
detect plant lectin binding and goat anti-human IgG-Fc FITC
(Jackson Labs) for the C-type lectin-Fc constructs. Cells were
washed with 100 μL PBS or HBSS (0.5% BSA) and subsequently
resuspended in 100 μL PBS or HBSS (0.5% BSA). Fluorescence
intensities were measured using either the FACSCaliburTM (BD
Bioscience, New Jersey, USA) or the CyAn ADP (Beckman Coulter,
Brea, USA) flow cytometers and cytometric data analysis was per-
formed with the FlowJo V10 software.
Inhibitors of glycosylation
MC38 cells were treated with 10 μg/mL Kifunensine (mannosidase I
inhibitor) (Sigma Aldrich), 2 mM Benzyl-α-GalNAc (O-glycosylation
inhibitor) (Sigma Aldrich), 1 μM 1-phenyl-2-palmitoylamino-3-mor-
pholino-1-propanol (PPMP, glucosphingolipid synthesis inhibitor)
(Enzo Life Sciences, Brussels, Belgium) or 0–100 μg/mL 2F-peracetyl
fucose (2F-PF) (general fucosyltransferase inhibitor) (Merck, New
Jersey, USA) according to manufacturer’s instructions for 48 h
before cells were analyzed by flow cytometry.
N-glycan release
MC38 cells were washed three times with PBS and dried cell pellets
(3 × 106/cell line) were frozen until further use. Upon thawing, the
cell pellets were resuspended in 100 μL pure water and were homo-
genized for 45min in a sonication bath in order to disrupt the cell
membranes. After sonication, the samples were centrifuged (500 ×
g, 15 min) and 17.5 μL of pure water was added to each sample and
mixed. 5 μL of reaction buffer (250mM sodium phosphate buffer;
pH 7.5) and 1.25 μL of denaturation buffer (2% SDS in 1M β-
mercaptoethanol) was added. The samples were incubated for
10min at 100°C to denature the proteins. After cooling the samples
to room temperature, 1.25 μL of Triton X-100 and 500 units of
PNGase F (QABio, California, USA) were added to each sample.
Samples were vortexed and incubated overnight at 37°C. The
released glycans were then converted to aldoses with 0.1% formic
acid, filtered through a protein-binding membrane and dried (Royle
et al. 2006).
Glycan labeling
Released N-glycans were fluorescently labeled by reductive amina-
tion with procainamide as described previously (Kozak et al. 2015)
using LudgerTagTM Procainamide Glycan Labelling Kit (LT-
KPROC-24). Briefly, samples in 10 μL of pure water were incubated
for 60min at 65°C with procainamide labeling solution. The procai-
namide labeled samples were cleaned-up using a Ludger clean plate
(LC-PROC-96). The purified procainamide labeled N-glycans were
eluted with pure water (100 μL). The samples were dried by vacuum
centrifugation and resuspended in pure water (100 μL) for further
analysis.
Liquid chromatography mass-spectrometry (LC–MS)
Procainamide labeled samples and system suitability standards were
analyzed by HILIC-(U)HPLC-ESI-MS with fluorescence detection.
Samples were injected in 24% pure water/76% acetonitrile (injection
volume 25 μL) onto an ACQUITY UPLC® BEH-Glycan 1.7 μm, 2.1 ×
150mm column at 40°C on a Ultimate 3000 UHPLC instrument
(Thermo Scientific, Massachusetts, USA) with a fluorescence detector
(λex = 310 nm, λem = 370 nm). The running conditions used were:
Solvent A was 50mM ammonium formate pH 4.4 made from Ludger
Stock Buffer (Ludger), and solvent B was acetonitrile. Gradient condi-
tions were: 0–38.5min, 76–58% B; 38.5–40.5min, 58–40.5% B at a
flow rate of 0.4mL/min; 40.5–42.5min, 40% B at a flow rate of
0.25mL/min; 42.5–44.5min, 40–76% B at a flow rate of 0.25mL/
min; 44.5–50.5min, 76% B at a flow rate of 0.25mL/min; 50.5–51.5min,
76% B at a flow rate of 0.25mL/min; 51.5–55min, 76% B at a
flow rate of 0.4mL/min. The UHPLC system was coupled on-line to
an AmaZon Speed ETD electrospray mass spectrometer (Bruker
Daltonics, Bremen, Germany) with the following settings: source
temperature 250°C, gas flow 10 L/min; Capillary voltage 4500 V;
ICC target 200,000; maximum accumulation time 50ms; rolling
average 2; number of precursors ions selected 3, release after
0.2min; Positive ion mode; Scan mode: enhanced resolution; mass
range scanned, 180–1500; Target mass, 700. A glucose homopoly-
mer ladder labeled with procainamide (Ludger) was used as a system
suitability standard as well as an external calibration standard for
GU allocation. ESI-MS and MS/MS data analysis was performed
using Bruker Compass DataAnalysis V4.1 software and
GlycoWorkbench software (Ceroni et al. 2008). The relative abun-
dance of identified N-linked glycans was determined as follows:
(Number of N-glycans matching the formulas listed in Table I/total
number of N-glycans identified for each cell line) ∗ 100%.
Statistical analysis
All statistical analyses were performed with the Prism software
(GraphPad V8 Software). Statistical significance was determined by a
Student’s unpaired t test with Welch’s correction: *P < 0.05, **P <
0.01, *** P < 0.001.
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Supplementary data is available at Glycobiology online.
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